Golimumab (anti-TNF)
Janssen (Simponi; repurposed)
What it is
An anti-TNF monoclonal antibody tested in the T1GER phase-2 trial in children and young adults with new-onset T1D. It preserved C-peptide and reduced insulin use over one year, with off-therapy follow-up signals. It is not approved for T1D and has never been shown to prevent onset. A TrialNet platform substudy registered with an estimated 8 August 2026 start would be the first test of it in presymptomatic, normal-glucose stage-1 T1D — the live registry is still not-yet-recruiting.
Editorial review: .
Most recent recorded citation date: 2026-07-06. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.See the linked studies and their populations →
- Benefit or performance
- Delay of onset: New-onset T1GER preserved C-peptide at 52 weeks, but golimumab has never been shown to delay clinical onset. That is now being tested directly: the primary endpoint of the new stage-1 platform substudy is time to confirmed dysglycemia or clinical diabetes.[1]
- Important harms and treatment burden
- Safety: Anti-TNF drugs have broad inflammatory-disease experience, but infection risk and chronic immune suppression are important concerns for young T1D patients.[4]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Two-year follow-up reported continued off-therapy metabolic improvements, but the evidence base remains one main phase-2 program.[2]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 48 × 30 + 45 × 20 + 52 × 20 + 30 × 15 + 20 × 15 = 4130; divide by total weight 100. Unrounded weighted result: 41.3.
New-onset T1GER preserved C-peptide at 52 weeks, but golimumab has never been shown to delay clinical onset. That is now being tested directly: the primary endpoint of the new stage-1 platform substudy is time to confirmed dysglycemia or clinical diabetes.[1]
Two-year follow-up reported continued off-therapy metabolic improvements, but the evidence base remains one main phase-2 program.[2]
Anti-TNF drugs have broad inflammatory-disease experience, but infection risk and chronic immune suppression are important concerns for young T1D patients.[4]
Efficacy evidence is new-onset (stage 3) only. A TrialNet stage-1 substudy (NCT07683026) is registered but still not-yet-recruiting as of the 6 July 2026 registry update (estimated start 8 August 2026 has passed without a status change; one site; readout ~2032) — a plan, not evidence. Earlier presymptomatic attempts were an 8-person phase-1b that tested safety alone and a stage-2 prevention trial withdrawn without enrolling anyone.[5]
Marketed for other autoimmune diseases but not T1D; diabetes use is investigational/off-label and biologic pricing limits reach.[4]
Editor’s take
Golimumab is too important to omit: T1GER was a clean pediatric/young-adult signal that anti-TNF biology can preserve beta-cell function. The quiet news of 2026 is that TrialNet is finally taking that signal upstream — into people who are autoantibody-positive but still have normal glucose. It is a real prevention attempt, not a press release. The estimated start was 8 August 2026; as of 27 August 2026 the registry is still not-yet-recruiting (last update 6 July 2026). It would read out around 2032. Golimumab remains a repurposed chronic biologic with safety and access baggage. Nothing about this makes it a practical prevention tool today.
The full picture
What it tested
Golimumab is an antibody against tumor necrosis factor alpha (TNF-alpha), a major inflammatory cytokine. The T1GER study tested whether blocking TNF soon after diagnosis could preserve the beta cells that remain.
Evidence and limits
T1GER randomized 84 children and young adults aged 6-21 with new-onset T1D to golimumab or placebo for 52 weeks. C-peptide was significantly higher with golimumab at week 52, insulin use was lower, and partial remission was more common.1
This is beta-cell preservation, not a demonstrated prevention of T1D onset. Anti-TNF therapy also carries chronic immune-suppression considerations that weigh heavily when the candidate population is young and otherwise healthy.
New in 2026: the first real prevention trial
Everything above happened after diagnosis. TrialNet and the NIDDK have registered a phase-2 golimumab substudy (protocol TN39A, NCT07683026) inside an adaptive platform trial aimed squarely at prevention — but as of 27 August 2026 it has not opened.5
It plans to enrol 255 people aged 2 to 44 (the registry's estimated structured-field figure; its free text says 225 — see caveats below) who have presymptomatic T1D — either two or more islet autoantibodies, or a confirmed IA-2A antibody alone — and who still have normal glucose tolerance on an oral glucose tolerance test. That is stage 1: the immune attack has started, but blood sugar has not budged yet. Participants are randomised 1:2 to placebo or golimumab, given as weight-based loading doses at weeks 0 and 2 and then monthly. The primary endpoint is the one that matters — how long it takes to develop confirmed dysglycemia or overt, symptomatic diabetes.
Some honest caveats, because the calendar is long and the details are unsettled:
- The trial is still not yet recruiting. Estimated start was 8 August 2026; that date has passed, and the last registry update is 6 July 2026. Estimated primary completion remains around September 2032. A passed start date is not enrollment. Nobody will know whether this works for about six years.
- Only one site (Joslin Diabetes Center, Boston) is listed so far, despite the protocol describing itself as multicentre.
- The registry entry contradicts itself: the structured fields say 255 participants, ages 2-44, while the free-text description says 225 participants and refers to people under 18. The record looks mid-revision. We cite the structured fields and will correct this if it settles differently.
This is not the first time golimumab has been given to someone before diagnosis, but TN39A is designed to be the first full-scale test. A Janssen phase-1b in stage-2 presymptomatic T1D (NCT03298542) enrolled just 8 people, tested safety only, and never posted results. A separate NIDDK stage-2 prevention trial (NCT04729296) was withdrawn during COVID-19 without enrolling anyone. TN39A would be the first anti-TNF trial in stage 1, and the first adequately powered presymptomatic attempt — if it opens and enrols as registered.
Until it reads out, the honest position stands: golimumab preserves beta-cell function in people who already have T1D, and may delay onset in people who don't. Only one of those is proven.
Coming soon
ETA · Phase-2 stage-1 prevention substudy registered with an estimated 8 August 2026 start; still not-yet-recruiting as of the 6 July 2026 registry update. Onset-delay data ~6 years away.
- →TrialNet adaptive-platform substudy (NCT07683026) — golimumab (loading doses, then monthly) vs placebo in about 255 normoglycaemic, autoantibody-positive people aged 2-44 (registry structured-field estimate; record free text says 225); primary endpoint is time to dysglycemia or clinical T1D · Estimated start 8 August 2026 has passed; registry still not-yet-recruiting as of 6 July 2026; ~6-year study
Sources
- [1]Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes · Peer-reviewed study · 2020-11-19 — PMID 33207093. Phase 2; n=84; ages 6-21; 4-hour C-peptide AUC at week 52 0.64 vs 0.43 pmol/mL (P<0.001).
Quattrin T, et al. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. New England Journal of Medicine (2020).
- [2]Two-Year Follow-up From the T1GER Study · Peer-reviewed study · 2023-03-01 — PMID 36576974. Off-therapy metabolic follow-up after golimumab.
- [3]A Study of SIMPONI to Arrest Beta-cell Loss in Type 1 Diabetes · Trial registry · 2025-02-04 — ClinicalTrials.gov NCT02846545; completed; actual enrollment 84.
- [4]SIMPONI (golimumab) prescribing information · Regulatory decision · 2019-10-01 — FDA label for approved non-T1D indications; no T1D indication.
- [5]Adaptive Platform Trial to Delay Progression From Normoglycemia to Dysglycemia in Presymptomatic Type 1 Diabetes — Golimumab Substudy · Trial registry · 2026-07-06 — NIDDK/TrialNet protocol TN39A; phase 2; still not-yet-recruiting as of last update 6 July 2026; n=255; ages 2-44; randomised 1:2 placebo:golimumab; estimated start 8 Aug 2026 has passed without a status change; primary completion Sept 2032. The registry record is internally inconsistent — the free-text description says 225 participants and refers to persons under 18, while the structured fields say 255 and ages 2-44. The structured fields are cited here. Live-checked 27 August 2026.
Adaptive Platform Trial to Delay Progression From Normoglycemia to Dysglycemia in Presymptomatic Type 1 Diabetes — Golimumab Substudy. ClinicalTrials.gov NCT07683026 (NIDDK/TrialNet, protocol TN39A; live-checked 27 August 2026).